Dosing chart / Growth hormone

CJC-1295 with DAC dosage

Also known as: DAC:GRF

What is CJC-1295 with DAC?

CJC-1295 with DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH), studied in clinical trials sponsored by the company ConjuChem. It is a modified 29-amino-acid GHRH fragment joined to a drug affinity complex (DAC), a chemical group that bonds to albumin, a common blood protein. That bond is what separates it from CJC-1295 without DAC (Mod GRF 1-29), which has no DAC group and is a different, shorter-acting molecule.

How it works

Like natural GHRH, it stimulates the pituitary gland to release the body's own growth hormone, which in turn raises IGF-1, a growth factor made mainly in the liver. Because the DAC group attaches the peptide to albumin, it stays in the blood for days; in healthy adults its estimated half-life was about 6 to 8 days.

What the evidence shows

Human evidence is limited to early-stage studies of hormone levels. Two randomized, placebo-controlled, double-blind trials in healthy adults aged 21 to 61 found that a single injection raised average growth hormone 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9 to 11 days. A second study in healthy men found that natural growth hormone pulses continued while baseline levels rose. A Phase 2 trial in people with HIV and visceral obesity was terminated in 2006, and no results were posted to the trial registry. There are no completed human trials showing benefits for body composition, performance or any disease; the albumin-binding design was first tested in rats.

Reported side effects

  • No serious adverse reactions were reported in the published healthy-volunteer trials, which were short
  • Increased heart rate, listed by the FDA as a serious adverse event associated with CJC-1295
  • Systemic vasodilatory reaction (body-wide flushing with widened blood vessels), also listed by the FDA

Cautions

  • Long-term safety is unknown; published human studies lasted weeks, not years.
  • The effect of one injection lasts many days and builds with repeated doses, so its effects persist well after an injection.
  • The FDA lists CJC-1295 among bulk substances that may present significant safety risks when compounded and notes that clinical data are limited.
  • Products sold as research compounds have uncertain purity, dose consistency and sterility.
  • Competitive athletes risk a multi-year ban; CJC-1295 is prohibited in sport at all times.

Legal and regulatory status

CJC-1295 with DAC is not an FDA-approved drug; a Phase 2 trial was terminated in 2006. The FDA includes CJC-1295 on its list of bulk substances that may present significant safety risks in compounding. GHRH and its synthetic analogs are prohibited by WADA, and USADA lists CJC-1295 as prohibited at all times.

Common questions

What does DAC mean in CJC-1295 with DAC?

DAC stands for drug affinity complex. It is a chemical group that lets the peptide bond to albumin in the bloodstream, which protects it from being cleared quickly and extends its half-life to roughly a week.

Is CJC-1295 with DAC FDA approved?

No. It was studied in early human trials, and a Phase 2 trial in people with HIV and visceral obesity was terminated in 2006 without posted results.

Does CJC-1295 with DAC build muscle or burn fat?

That has not been shown in people. Published human studies measured growth hormone and IGF-1 levels in healthy volunteers, not muscle, fat or performance, and no completed efficacy trial has been published.

Sources

  1. Journal of Clinical Endocrinology and Metabolism (2006): Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
  2. Journal of Clinical Endocrinology and Metabolism (2006), PubMed record 17018654: Pulsatile GH secretion persists during CJC-1295 stimulation
  3. Endocrinology (2005), PubMed record 15817669: hGRF(1-29)-albumin bioconjugates and identification of CJC-1295
  4. ClinicalTrials.gov: NCT00267527, CJC 1295 in HIV patients with visceral obesity
  5. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
  6. Frontiers in Endocrinology (2026): Performance-enhancing peptides modulating the GH-IGF1 axis
  7. Drug Testing and Analysis (2021), PubMed record 34665524: Detection of GHRH synthetic analogs
  8. USADA: Anthony McCauley accepts doping sanction

CJC-1295 with DAC reviews and Q&A

TopicRepliesLast activity

No reviews or questions yet. Be the first.

More in Growth hormone

Compare CJC-1295 with DAC

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.